Emilio Emini, senior vice president of vaccine research and development at Pfizer, explained that, shortly after the outbreak at the University at the end of 2013, the FDA asked Pfizer if the company felt it had sufficient data to apply for accelerated approval.
explained that Trumenba had been in research and development for over 10 years.
added that serogroup B was the only serogroup not covered by existing vaccines and that many cases of meningitis B had been reported over the years.
"Obviously, you had the outbreak in Princeton last year, and after that, you saw it reported more in the news, but serogroup B cases are reported all the time," Emini
explained that shortly after the outbreak at the University at the end of 2013, the FDA
if the company felt that it had sufficient data to apply for accelerated approval.
felt that its data had met the requirements, it decided to apply.
explained that the vaccine specifically targets individuals between the ages of 10 and 25, since a majority of the cases involving this disease have been identified in adolescents and young adults.
added that the meningococcal bacterium is typically transmitted among adolescents and young adults and that this age group is also largely responsible for transmitting the disease to other people.
Older adults and young infants, who also tend to be more vulnerable to the disease, typically receive the bacterium through transmission from adolescents and young adults, Emini